Literature DB >> 15937762

Three broad modalities in the natural history of vertically acquired hepatitis C virus infection.

.   

Abstract

BACKGROUND: Little is known about the natural history of vertically acquired hepatitis C virus (HCV) infection.
METHODS: We performed a large, multicenter, prospective study of children born to HCV-infected women in Europe. Children were considered to be infected on the basis of > or = 2 polymerase chain reaction (PCR) test results positive for HCV RNA and/or test results positive for anti-HCV antibody > 18 months after birth.
RESULTS: Two hundred sixty-six children with vertical HCV infection were followed up until a median of 4.2 years of age (range, 3.2 months to 15.9 years of age). Twenty-six children were coinfected with human immunodeficiency virus. Hepatomegaly, the only clinical sign reported, was found in 10% of children and was significantly associated with a high proportion of abnormal alanine transaminase (ALT) levels (adjusted odds ratio [OR], 4.17; 95% confidence interval [CI], 1.67-10.42; P = .002). An estimated 21%-25% of children may have cleared the virus (i.e., had 2 consecutive PCR test results negative for HCV RNA, normal ALT levels, and no clinical signs) at a median age of 14.9 months. A high proportion of positive PCR test results obtained in the first year of life was associated with a lower likelihood of clearance (OR, 9.77; 95% CI, 2.92-32.67; P < .0001) and persistent viremia in children > 1 year old (adjusted OR, 2.92; 95% CI, 1.09-7.80; P = .03).
CONCLUSIONS: We confirm the low prevalence of HCV-related clinical signs and symptoms among vertically infected children in the first 10-15 years of life. Approximately 20% of children appear to clear the infection, 50% have evidence of chronic asymptomatic infection, and 30% have evidence of chronic active infection. Although viremia and abnormal ALT levels were associated with hepatomegaly, further investigation is necessary before these markers can be used in the clinical management of HCV infection in children.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937762     DOI: 10.1086/430601

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  51 in total

1.  IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.

Authors:  Vito Di Marco; Fabrizio Bronte; Vincenza Calvaruso; Marcello Capra; Zelia Borsellino; Aurelio Maggio; Maria Concetta Renda; Lorella Pitrolo; Maria Carmela Lo Pinto; Michele Rizzo; Flavia Fiorenza; Calogera Gerardi; Stefania Grimaudo; Antonietta Di Cristina; Massimo Levrero; Antonio Craxì
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

2.  The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.

Authors:  Kathleen B Schwarz; Regino P Gonzalez-Peralta; Karen F Murray; Jean P Molleston; Barbara A Haber; Maureen M Jonas; Philip Rosenthal; Parvathi Mohan; William F Balistreri; Michael R Narkewicz; Lesley Smith; Steven J Lobritto; Stephen Rossi; Alexandra Valsamakis; Zachary Goodman; Patricia R Robuck; Bruce A Barton
Journal:  Gastroenterology       Date:  2010-10-28       Impact factor: 22.682

3.  Vertical transmission of the hepatitis C virus: Current knowledge and issues.

Authors: 
Journal:  Paediatr Child Health       Date:  2008-07       Impact factor: 2.253

4.  Hepatitis C viral infection in children.

Authors:  Douglas Mogul; Kathleen B Schwarz
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-07-23

5.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

6.  Natural history of vertically acquired HCV infection and associated autoimmune phenomena.

Authors:  Silvia Garazzino; Carmelina Calitri; Antonella Versace; Alda Alfarano; Carlo Scolfaro; Chiara Bertaina; Simona Vatrano; Federica Mignone; Francesco Licciardi; Clara Gabiano; Pier-Angelo Tovo
Journal:  Eur J Pediatr       Date:  2014-03-04       Impact factor: 3.183

7.  Hepatitis C Testing Among Perinatally Exposed Infants.

Authors:  Susan M Lopata; Elizabeth McNeer; Judith A Dudley; Carolyn Wester; William O Cooper; James G Carlucci; Claudia M Espinosa; William Dupont; Stephen W Patrick
Journal:  Pediatrics       Date:  2020-02-14       Impact factor: 7.124

Review 8.  Is liver biopsy still needed in children with chronic viral hepatitis?

Authors:  Maria Pokorska-Śpiewak; Barbara Kowalik-Mikołajewska; Małgorzata Aniszewska; Magdalena Pluta; Magdalena Marczyńska
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages.

Authors:  Fatma M Shebl; Samer S El-Kamary; Doa'a A Saleh; Mohamed Abdel-Hamid; Nabiel Mikhail; Alif Allam; Hanaa El-Arabi; Ibrahim Elhenawy; Sherif El-Kafrawy; Mai El-Daly; Sahar Selim; Ayman Abd El-Wahab; Mohamed Mostafa; Soraya Sharaf; Mohamed Hashem; Scott Heyward; O Colin Stine; Laurence S Magder; Sonia Stoszek; G Thomas Strickland
Journal:  J Med Virol       Date:  2009-06       Impact factor: 2.327

10.  Managing pediatric hepatitis C: current and emerging treatment options.

Authors:  Wikrom Karnsakul; Mary Kay Alford; Kathleen B Schwarz
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.